vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $124.5M, roughly 1.4× PagerDuty, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
ESPR vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $124.5M |
| Net Profit | — | $161.6M |
| Gross Margin | — | 85.3% |
| Operating Margin | 50.6% | 6.5% |
| Net Margin | — | 129.7% |
| Revenue YoY | 143.7% | 4.7% |
| Net Profit YoY | — | 2827.7% |
| EPS (diluted) | $0.32 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $124.5M | ||
| Q3 25 | $87.3M | $123.4M | ||
| Q2 25 | $82.4M | $119.8M | ||
| Q1 25 | $65.0M | $121.4M | ||
| Q4 24 | $69.1M | $118.9M | ||
| Q3 24 | $51.6M | $115.9M | ||
| Q2 24 | $73.8M | $111.2M | ||
| Q1 24 | $137.7M | $111.1M |
| Q4 25 | — | $161.6M | ||
| Q3 25 | $-31.3M | $9.6M | ||
| Q2 25 | $-12.7M | $-7.2M | ||
| Q1 25 | $-40.5M | $-8.8M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-29.5M | $-10.9M | ||
| Q2 24 | $-61.9M | $-17.1M | ||
| Q1 24 | $61.0M | $-28.2M |
| Q4 25 | — | 85.3% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.7% |
| Q4 25 | 50.6% | 6.5% | ||
| Q3 25 | -11.4% | 2.9% | ||
| Q2 25 | 8.6% | -8.6% | ||
| Q1 25 | -34.0% | -9.6% | ||
| Q4 24 | -6.4% | -8.7% | ||
| Q3 24 | -31.0% | -13.8% | ||
| Q2 24 | 3.5% | -19.5% | ||
| Q1 24 | 52.5% | -30.1% |
| Q4 25 | — | 129.7% | ||
| Q3 25 | -35.9% | 7.8% | ||
| Q2 25 | -15.4% | -6.0% | ||
| Q1 25 | -62.2% | -7.2% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | -57.2% | -9.4% | ||
| Q2 24 | -83.9% | -15.4% | ||
| Q1 24 | 44.3% | -25.3% |
| Q4 25 | $0.32 | $1.69 | ||
| Q3 25 | $-0.16 | $0.10 | ||
| Q2 25 | $-0.06 | $-0.07 | ||
| Q1 25 | $-0.21 | $-0.12 | ||
| Q4 24 | $-0.14 | $-0.07 | ||
| Q3 24 | $-0.15 | $-0.14 | ||
| Q2 24 | $-0.33 | $-0.26 | ||
| Q1 24 | $0.34 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $547.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $320.5M |
| Total Assets | $465.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $547.8M | ||
| Q3 25 | $92.4M | $567.9M | ||
| Q2 25 | $86.1M | $597.1M | ||
| Q1 25 | $114.6M | $570.8M | ||
| Q4 24 | $144.8M | $542.2M | ||
| Q3 24 | $144.7M | $599.3M | ||
| Q2 24 | $189.3M | $592.8M | ||
| Q1 24 | $226.6M | $571.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | $-302.0M | $320.5M | ||
| Q3 25 | $-451.4M | $180.7M | ||
| Q2 25 | $-433.5M | $145.7M | ||
| Q1 25 | $-426.2M | $129.8M | ||
| Q4 24 | $-388.7M | $111.6M | ||
| Q3 24 | $-370.2M | $164.7M | ||
| Q2 24 | $-344.2M | $174.0M | ||
| Q1 24 | $-294.3M | $171.6M |
| Q4 25 | $465.9M | $1.0B | ||
| Q3 25 | $364.0M | $891.5M | ||
| Q2 25 | $347.1M | $926.8M | ||
| Q1 25 | $324.0M | $927.3M | ||
| Q4 24 | $343.8M | $866.8M | ||
| Q3 24 | $314.1M | $916.0M | ||
| Q2 24 | $352.3M | $924.0M | ||
| Q1 24 | $373.1M | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $24.8M |
| Free Cash FlowOCF − Capex | — | $24.1M |
| FCF MarginFCF / Revenue | — | 19.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $24.8M | ||
| Q3 25 | $-4.3M | $34.0M | ||
| Q2 25 | $-31.4M | $30.7M | ||
| Q1 25 | $-22.6M | $31.4M | ||
| Q4 24 | $-35.0M | $22.1M | ||
| Q3 24 | $-35.3M | $35.8M | ||
| Q2 24 | $-7.2M | $28.6M | ||
| Q1 24 | $53.8M | $22.2M |
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $33.1M | ||
| Q2 25 | — | $30.2M | ||
| Q1 25 | — | $30.3M | ||
| Q4 24 | — | $21.5M | ||
| Q3 24 | $-35.5M | $35.1M | ||
| Q2 24 | $-7.3M | $28.2M | ||
| Q1 24 | $53.8M | $21.2M |
| Q4 25 | — | 19.3% | ||
| Q3 25 | — | 26.8% | ||
| Q2 25 | — | 25.2% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | -68.7% | 30.3% | ||
| Q2 24 | -9.9% | 25.4% | ||
| Q1 24 | 39.0% | 19.1% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.4% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
